Novo Nordisk

Eli Lilly (LLY +3.90%) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of it...

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Key Points Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market. The drugmak...

Novo Nordisk (NYSE:NVO) has drawn fresh attention after recent share price moves, with the stock closing at US$45.97. Investors are weighing this level against...

Retail investors are feeling less healthy about the prospects of Hims & Hers (HIMS) as it gets set to report Q2 earnings next week – August 10th. Unlock powerf...

Dutch judges have issued a preliminary injunction against a European compounding firm, forcing an immediate halt to sales of an unauthorized semaglutide nasal s...

Key Points Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Novo Nordisk (NVO) to $47 from $45 and keeps a Market Perform rating on the shares. Novo No...

Amazon Pharmacy (AMZN) has joined a federal program to offer GLP-1 weight-loss drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) to eligible Medicare enrollees...

After a three year stretch where Novo Nordisk stock has declined 50.5%, the valuation picture now looks more supportive than the share price performance suggest...